Patents by Inventor Ryan Holcomb
Ryan Holcomb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210121536Abstract: Some embodiments provided herein relate to methods and pharmaceutical compositions comprising recombinant human surfactant protein D or active fragments thereof. Some such embodiments include solutions or suspensions, and lyophilized solid forms of recombinant human surfactant protein D or active fragments thereof.Type: ApplicationFiled: March 27, 2019Publication date: April 29, 2021Inventors: Jan Susan Rosenbaum, Mark Cornell Manning, Derrick S. Katayama, Giovanni M. Pauletti, Shawn Grant, Ryan Holcomb
-
Publication number: 20140288044Abstract: The invention relates to compounds, pharmaceutical compositions and medicaments comprising such compounds, and the use of these compounds, compositions, and medicaments in methods of treating diseases and disorders.Type: ApplicationFiled: April 12, 2012Publication date: September 25, 2014Applicant: Alzheimer's Institute of America, Inc.Inventors: Ryan Holcomb, Paul R. Sebahar, Kazuyuki Suzuki, Donald A. McLeod, David M. Dastrup, Christophe Hoarau, Robert J. Halter, Matthew Gregory Bursavich, Mark D. Shenderovich, Burt Richards, Paul L. Bartel
-
Publication number: 20070093485Abstract: Disclosed are certain substituted N-phenylsulfonamide derivatives and related compounds. These compounds are useful as bradykinin antagonists to relieve adverse symptoms in mammals mediated, at least in part, by bradykinin including pain, inflammation, bronchoconstriction, cerebral edema, etc.Type: ApplicationFiled: December 18, 2003Publication date: April 26, 2007Inventors: Francine Farouz, Michael Dappen, Ying-Zi Xu, Sarah Bartulis, Ryan Holcomb, Ramesh Kasar, Michael Pleiss, Eugene Thorsett, Xiaocong Ye, Andrei Konradi
-
Publication number: 20070032475Abstract: Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor.Type: ApplicationFiled: April 6, 2006Publication date: February 8, 2007Inventors: Xiaocong Ye, Albert Garofalo, Rose Lawler, Juri Fukuda, Andrei Konradi, Ryan Holcomb, Kassandra Rossiter, David Wone, Jing Wu
-
Patent number: 7056937Abstract: Disclosed are 1-sulfonylquioxalone acetamides and derivatives thereof. The compounds are exemplified by compounds of the formula: Such compounds, derivatives and related compounds are useful as bradykinin antagonists.Type: GrantFiled: May 2, 2003Date of Patent: June 6, 2006Assignee: Elan Pharmaceuticals, Inc.Inventors: Francine S. Grant, Sarah Bartulis, Louis Brogley, Michael S. Dappen, Ramesh Kasar, Ryan Holcomb, Michael A. Pleiss, Eugene D. Thorsett, Michael Ye, Jon E. Hawkinson
-
Publication number: 20040147519Abstract: Disclosed are sulfonylquinoxalone acetamide derivatives useful as bradykinin antagonists.Type: ApplicationFiled: May 2, 2003Publication date: July 29, 2004Inventors: Francine S. Grant, Sarah Bartulis, Louis Brogley, Michael S. Dappen, Ramesh Kasar, Ryan Holcomb, Michael A. Pleiss, Eugene D. Thorsett, Michael Ye, Jon E. Hawkinson
-
Patent number: 6518268Abstract: Thiazolidinedione compounds, compositions, and methods of inhibiting telomerase activity in vitro and treatment of telomerase mediated conditions or diseases ex vivo and in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of conditions or diseases mediated by telomerase activity, such as in the treatment of cancer. Also disclosed are novel methods for assaying or screening for inhibitors of telomerase activity.Type: GrantFiled: June 30, 2000Date of Patent: February 11, 2003Assignees: Geron Corporation, Kyowa Hakko Kogyo Co., Ltd.Inventors: Allison C. Chin, Ryan Holcomb, Mieczyslaw A. Piatyszek, Upinder Singh, Richard L. Tolman, Tsutomu Akama, Yutaka Kanda, Akira Asai, Yoshinori Yamashita, Kaori Endo, Hiroyuki Yamaguchi
-
Patent number: 6452014Abstract: Thiazolidinedione compounds, compositions, and methods of inhibiting telomerase activity in vitro and treatment of telomerase mediated conditions or diseases ex vivo and in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of conditions or diseases mediated by telomerase activity, such as in the treatment of cancer. Also disclosed are methods for assaying or screening for inhibitors of telomerase activity.Type: GrantFiled: December 22, 2000Date of Patent: September 17, 2002Assignee: Geron CorporationInventors: Tsutomu Akama, Ryan Holcomb, Richard L. Tolman
-
Publication number: 20020120144Abstract: Thiazolidinedione compounds, compositions, and methods of inhibiting telomerase activity in vitro and treatment of telomerase mediated conditions or diseases ex vivo and in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of conditions or diseases mediated by telomerase activity, such as in the treatment of cancer. Also disclosed are methods for assaying or screening for inhibitors of telomerase activity.Type: ApplicationFiled: December 22, 2000Publication date: August 29, 2002Inventors: Tsutomu Akama, Ryan Holcomb, Richard L. Tolman
-
Publication number: 20020115700Abstract: 5-(3-Isatinylidinyl)thiazolidineones and 3-(thiazolidinon-5-yl)indoles compounds, compositions, and methods of inhibiting telomerase activity in vitro and treatment of telomerase mediated conditions or diseases ex vivo and in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of conditions or diseases mediated by telomerase activity, such as in the treatment of cancer. Also disclosed are novel methods for assaying or screening for inhibitors of telomerase activity.Type: ApplicationFiled: February 13, 2002Publication date: August 22, 2002Inventors: Allison C. Chin, Richard L. Tolman, Mark Q. Nguyen, Ryan Holcomb
-
Patent number: 6372742Abstract: 5-(3-Isatinylidinyl)thiazolidineones and 3-(thiazolidinon-5-yl)indoles compounds, compositions, and methods of inhibiting telomerase activity in vitro and treatment of telomerase mediated conditions or diseases ex vivo and in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of conditions or diseases mediated by telomerase activity, such as in the treatment of cancer. Also disclosed are novel methods for assaying or screening for inhibitors of telomerase activity.Type: GrantFiled: June 30, 2000Date of Patent: April 16, 2002Assignee: Geron CorporationInventors: Allison C. Chin, Richard L. Tolman, Mark Q. Nguyen, Ryan Holcomb
-
Patent number: 6274738Abstract: The invention provides DNA primase assays suitable for identifying DN primase modulating agents, methods of modulating DNA primase activity, compounds for modulating DNA primase activity, and compositions which modulate DNA primase.Type: GrantFiled: November 24, 1997Date of Patent: August 14, 2001Assignee: Geron CorporationInventors: Michael R. Kozlowski, Junko Aimi, Ryan Holcomb
-
Patent number: 5877296Abstract: This invention describes carrier-drug conjugates prepared from disulfide analogs of the calicheamicin family of potent antitumor antibiotics and their derivatives, as well as similar analogs from related antitumor antibiotics such as the esperamicins. The carrier can be an antibody, growth factor, or steroid which targets an undesired population of cells, such as those of a tumor. Whole protein carriers as well as their antigen-recognizing fragments and their chemically or genetically manipulated counterparts are useful for the targeting portion of the conjugates. This invention includes compounds required for the synthesis of these conjugates, appropriate pharmaceutical compositions of the carrier-drug conjugates, and their method of use.Type: GrantFiled: May 26, 1995Date of Patent: March 2, 1999Assignee: American Cyanamid CompanyInventors: Philip Ross Hamann, Lois Hinman, Irwin Hollander, Ryan Holcomb, William Hallett, Hwei-Ru Tsou, Martin J. Weiss
-
Patent number: 5773001Abstract: This invention describes carrier-drug conjugates prepared from disulfide analogs of the calicheamicin family of potent antitumor antibiotics and their derivatives, as well as similar analogs from related antitumor antibiotics such as the esperamicins. The carrier can be an antibody, growth factor, or steroid which targets an undesired population of cells, such as those of a tumor. Whole protein carriers as well as their antigen-recognizing fragments and their chemically or genetically manipulated counterparts are useful for the targeting portion of the conjugates. This invention includes compounds required for the synthesis of these conjugates, appropriate pharmaceutical compositions of the carrier-drug conjugates, and their method of use.Type: GrantFiled: June 3, 1994Date of Patent: June 30, 1998Assignee: American Cyanamid CompanyInventors: Philip Ross Hamann, Lois Hinman, Irwin Hollander, Ryan Holcomb, William Hallett, Hwei-Ru Tsou, Martin J. Weiss
-
Patent number: 5767285Abstract: This invention describes carrier-drug conjugates prepared from disulfide analogs of the calicheamicin family of potent antitumor antibiotics and their derivatives, as well as similar analogs from related antitumor antibiotics such as the esperamicins. The carrier can be an antibody, growth factor, or steroid which targets an undesired population of cells, such as those of a tumor. Whole protein carriers as well as their antigen-recognizing fragments and their chemically or genetically manipulated counterparts are useful for the targeting portion of the conjugates. This invention includes compounds required for the synthesis of these conjugates, appropriate pharmaceutical compositions of the carrier-drug conjugates, and their method of use.Type: GrantFiled: June 5, 1995Date of Patent: June 16, 1998Assignee: American Cyanamid CompanyInventors: Philip Ross Hamann, Lois Hinman, Irwin Hollander, Ryan Holcomb, William Hallett, Hwei-Ru Tsou, Martin J. Weiss
-
Patent number: 5739116Abstract: This invention describes carrier-drug conjugates prepared from disulfide analogs of the calicheamicin family of potent antitumor antibiotics and their derivatives, as well as similar analogs from related antitumor antibiotics such as the esperamicins. The carrier can be an antibody, growth factor, or steroid which targets an undesired population of cells, such as those of a tumor. Whole protein carriers as well as their antigen-recognizing fragments and their chemically or genetically manipulated counterparts are useful for the targeting portion of the conjugates. This invention includes compounds required for the synthesis of these conjugates, appropriate pharmaceutical compositions of the carrier-drug conjugates, and their method of use.Type: GrantFiled: June 5, 1995Date of Patent: April 14, 1998Assignee: American Cyanamid CompanyInventors: Philip Ross Hamann, Lois Hinman, Irwin Hollander, Ryan Holcomb, William Hallett, Hwei-Ru Tsou, Martin J. Weiss